Qingyi He

Qingyi He


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
LLLi Li
Li Li
HLHongwei Lu
Hongwei Lu
YZYulan Zhao
Yulan Zhao
JLJiangming Luo
Jiangming Luo
LYLi Yang
Li Yang
QHQingyi He
Qingyi He

14 December 2019 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
PDF file
JHJunxian Hu
Junxian Hu
XLXianghe Li
Xianghe Li
YCYueqi Chen
Yueqi Chen
XHXinyun Han
Xinyun Han
LLLi Li
Li Li
QHQingyi He
Qingyi He
The balance between bone formation and bone resorption is closely related to bone homeostasis. Osteoclasts, originating from the monocyte/macrophage lineage, are the only cell type possessing bone resorption ability. Osteoclast overactivity is thought to be the major reason underlying osteoclast‐related osteolytic problems, such as Paget's disease, aseptic loosening of prostheses and inflammatory osteolysis; therefore, disruption of osteoclastogenesis is considered a crucial treatment option for these issues. WKYMVm, a synthetic peptide, which is a potent FPR2 agonist, exerts an immunoregulatory effect. This peptide inhibits the production of inflammatory cytokines, such as (IL)‐1β and TNF‐α, thus regulating inflammation. However, there are only few reports on the role of WKYMVm and FPR2 in osteoclast cytology. In the current study, we found that WKYMVm negatively regulates RANKL‐ and lipopolysaccharide (LPS)‐induced osteoclast differentiation and maturation in vitro and alleviates LPS‐induced osteolysis in animal models. WKYMVm down‐regulated the expression of osteoclast marker genes and resorption activity. Furthermore, WKYMVm inhibited osteoclastogenesis directly through reducing the phosphorylation of STAT3 and NF‐kB and indirectly through the CD9/gp130/STAT3 pathway. In conclusion, our findings demonstrated the potential medicinal value of WKYMVm for the treatment of inflammatory osteolysis.

24 December 2019 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LLLi Li
Li Li
WLWanqian Liu
Wanqian Liu
YZYulan Zhao
Yulan Zhao
PMPingping Ma
Pingping Ma
SZShenfang Zha
Shenfang Zha
QHQingyi He
Qingyi He

Verified
Closed access
科臣科张 臣
科张 臣
锦衍锦卢 衍
锦卢 衍
鹏宇鹏郭 宇
鹏郭 宇
陈万陈 万
陈 万
唐红唐 红
唐 红
QHQingyi He
Qingyi He

16 May 2024 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
LLLi Li
Li Li
WLWanqian Liu
Wanqian Liu
YZYulan Zhao
Yulan Zhao
PMPingping Ma
Pingping Ma
SZShenfang Zha
Shenfang Zha
QHQingyi He
Qingyi He